Array Biopharma, Inc. (ARRY) Posts Narrower than Expected Q1 Loss
Tweet Send to a FriendGet Alerts ARRY Hot Sheet
Trade ARRY Now!
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q1 EPS of ($0.11), $0.05 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $19.1 million versus the consensus estimate of $18.51 million.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Applied Materials, Inc. (AMAT) Tops Q2 EPS by 3c, Offers Guidance
- e-Future Information Technology, Inc. (EFUT) Widens Q1 Loss to RMB1.06/Share
- CNinsure, Inc. (CISG) Q1 EPS Falls to RMB0.67
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
